publication date: Dec. 4, 2020

NCI Trials

NCI Trials for December 2020

The National Cancer Institute approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase 0 – 10401

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Stone, Rebecca Lynn

(410) 955-8240

 

Phase I – 10387

Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection

Albert Einstein College of Medicine EDDOP

Cheng, Haiying

(718) 405-8404

 

Phase II – AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Children’s Oncology Group

Cooper, Stacy L.

(410) 502-7364

 

Phase II – S2001

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

SWOG

Chung, Vincent

(626) 256-4673

 

Phase III – EA8183

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

ECOG-ACRIN Cancer Research Group

Morgans, Alicia Katherine

(312) 695-2381

 

Phase III – S1931

Phase III Trial … Continue reading NCI Trials for December 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.